TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32399662
Drug: oGLD (intensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: oGLD (intensive therapy using other glucose-lowering drugs)
Study: 33901859
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy plus manual therapy (ET plus MT)
Study: 37032446
Drug: Baricitinib 4
Normalized name: baricitinib 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baricitinib 4 mg once daily
Study: 32580813
Drug: Medium-GAA (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-GAA (0.6 g/kg DM)
Study: 32580813
Drug: High-GAA (0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-GAA (0.9 g/kg DM)
Study: 32580813
Drug: GAA addition
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: GAA addition (0.3, 0.6, 0.9 g/kg DM)
Study: 32580813
Drug: Medium-GAA (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-GAA (0.6 g/kg DM) and High-GAA (0.9 g/kg DM)
Study: 39665235
Drug: Pindolol 15
Normalized name: pindolol 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol 15 mg
Study: 36323488
Drug: Biological DMARDs
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological DMARDs treatment
Study: 36323488
Drug: Prophylaxis treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylaxis treatment for Pneumocystis jirovecii
Study: 32843086
Drug: Third scheduled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third scheduled dose of human monovalent rotavirus vaccine (Rotarix)
Study: 32886932
Drug: 35 mg
Normalized name: papain 35 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 mg TMZ-modified release
Study: 32886932
Drug: 70 mg
Normalized name: silybin 70 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 mg TMZ-modified release
Study: 32886932
Drug: 105 mg
Normalized name: menthol 105 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 105 mg TMZ-modified release
Study: 32886932
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of TMZ-modified release
Study: 33880860
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma (PRP) treatment, intradermal and subdermal injection weekly for 4-6 sessions.
Study: 33880860
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (compression and dressing) for chronic venous leg ulcers.
Study: 33292924
Drug: Early structured
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early structured physiotherapy with a steroid injection
Study: 32909326
Drug: Sour tea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sour tea supplementation (450 mg capsule daily for 8 weeks)
Study: 32909326
Drug: Placebo (capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (capsule daily for 8 weeks)
Study: 33684370
Drug: TPEx regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPEx regimen (docetaxel 75 mg/m2, cisplatin 75 mg/m2, cetuximab 400 mg/m2 on day 1 of cycle 1 and 250 mg/m2 weekly thereafter)
Study: 33684370
Drug: EXTREME regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: EXTREME regimen (fluorouracil 4000 mg/m2 on days 1-4, cisplatin 100 mg/m2 on day 1, cetuximab 400 mg/m2 on day 1 of cycle 1 and 250 mg/m2 weekly thereafter)
Study: 32083490
Drug: LBPT tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: LBPT tablet
Study: 32865944
Drug: Low-dose topical
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose topical creatine cream (3.5 ml)
Study: 32865944
Drug: High-dose topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose topical creatine cream (7 ml)
Study: 32865944
Drug: Topical creatine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical creatine cream after 7-day supplementation
Study: 32865944
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream after 7-day supplementation
Study: 33864070
Drug: Insufficient 25(OH)D
Normalized name: 1α,25(OH)2D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insufficient 25(OH)D (<30 ng/ml)
Study: 34167567
Drug: Basiliximab induction
Normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Basiliximab induction therapy
Study: 32479321
Drug: Esketamine nasal
Normalized name: esketamine Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esketamine nasal spray + newly initiated oral antidepressant (esketamine+AD)
Study: 33388426
Drug: Shenmai injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenmai injection (SMI) combined with 5-fluorouracil (5-FU)
Study: 33388426
Drug: Shenmai injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenmai injection (SMI) combined with neoadjuvant chemotherapy
Study: 33388426
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (neoadjuvant chemotherapy without SMI)
Study: 35581440
Drug: Aducanumab (32
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aducanumab (32 monthly doses, titrated up to 6 mg/kg, cumulative dose of 186 mg/kg)
Study: 34523872
Drug: Subcutaneous specific
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous specific immunotherapy (SSI) with whole body bed bug extract
Study: 36434148
Drug: Mentalization-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mentalization-based treatment for adolescents with CD (MBT-CD)
Study: 32416981
Drug: Narcotic group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narcotic group (received acetaminophen, ibuprofen, and narcotic)
Study: 32416981
Drug: Nonnarcotic group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonnarcotic group (received acetaminophen and ibuprofen)
Study: 34975069
Drug: Scheduled phosphodiesterase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scheduled phosphodiesterase 5 inhibitor (PDE5i) 5 mg tadalafil once a day (OaD) combined with vacuum erectile device (VED)
Study: 34975069
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of VED and tadalafil OaD
Study: 34392138
Drug: Adherence monitoring
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adherence monitoring with audiovisual medication reminders
Study: 36175995
Drug: Maternal fecal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal fecal microbiota (FMT) administered orally in breast milk during the first feeding
Study: 36175995
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment administered orally in breast milk during the first feeding
Study: 34192430
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ZED1227
Study: 34192430
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg ZED1227
Study: 34192430
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg ZED1227
Study: 33632110
Drug: Immediate-release oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release oxycodone 30 mg
Study: 34395716
Drug: Piperacillin-tazobactam 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin-tazobactam 4.5 g every 6 hours
Study: 33123968
Drug: Trilaciclib 240
Normalized name: Trilaciclib
DrugBank: Trilaciclib (DB15442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trilaciclib 240 mg/m2
Study: 32394350
Drug: TP (docetaxel:
Approvals — FDA: no, EMA: no, PMDA: no
Description: TP (docetaxel: 75 mg/m2 or paclitaxel 175 mg/m2 d1; carboplatin AUC=5, day 1)
Study: 32394350
Drug: EC (epirubicin:
Approvals — FDA: no, EMA: no, PMDA: no
Description: EC (epirubicin: 90 mg/m2; cyclophosphamide: 600 mg/m2, day 1) followed by T (docetaxel: 75 mg/m2 or paclitaxel 175 mg/m2, day 1)
Study: 34692842
Drug: Lymphocyte active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymphocyte active immunotherapy
Study: 39014463
Drug: Anthracycline therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthracycline therapy
Study: 32311961
Drug: Curcuminoid complex
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcuminoid complex 500 mg with diclofenac 50 mg
Study: 32311961
Drug: Diclofenac 50
Normalized name: DICLOFENAC 50MG/MISOPROSTOL 200MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 50 mg alone
Study: 35031148
Drug: High-dose quadrivalent
Normalized name: Fluzone High-Dose Quadrivalent PF 2020-2021
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose quadrivalent influenza vaccine (Fluzone High-Dose Quadrivalent; QIV-HD)
Study: 33475271
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Ranibizumab with Verteporfin)
Study: 32948224
Drug: Egg white
Normalized name: EGG WHITE
DrugBank: Egg white (DB10528)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Egg white hydrolyzate (5 g/day)
Study: 34246687
Drug: Transmuscular QL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transmuscular QL block with 20 mL 0.375% ropivacaine
Study: 34246687
Drug: TAP block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAP block with 20 mL 0.375% ropivacaine
Study: 38986212
Drug: Osimertinib 80
Normalized name: osimertinib 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osimertinib 80 mg once daily
Study: 36533429
Drug: Chemotherapy (control)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (control)
Study: 33980526
Drug: Early calorie-protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early calorie-protein restriction (6 kcal/kg/day, 0.2-0.4 g/kg/day)
Study: 33980526
Drug: Standard calorie-protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard calorie-protein targets (25 kcal/kg/day, 1.0-1.3 g/kg/day)
Study: 34041932
Drug: Experimental vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental vaccine (details not specified)
Study: 34041932
Drug: Active comparator
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active comparator vaccine with established efficacy of 50%-70%
Study: 34041932
Drug: Active comparator
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active comparator vaccine with established efficacy of 90%-95%
Study: 35100468
Drug: Alb‐NC (cerium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alb‐NC (cerium oxide nanoparticles conjugated with albumin; 50 µg/ml)
Study: 35294962
Drug: Cocoa extract
Normalized name: Cocoa extract
DrugBank: Cocoa (DB10977)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa extract supplement (500 mg flavanols/d, including 80 mg (‐)‐epicatechin)
Study: 35294962
Drug: Cocoa extract
Normalized name: Cocoa extract
DrugBank: Cocoa (DB10977)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa extract supplement
Study: 33340120
Drug: mexiletine 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: mexiletine 300 or 600 mg daily for 4 weeks
Study: 33409020
Drug: Increasing fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing fluid therapy before surgery
Study: 34183577
Drug: 4-week TEA
Normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-week TEA treatment
Study: 34183577
Drug: TEA treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TEA treatment
Study: 32013700
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (AA) 200 mg/kg divided over 24 hours
Study: 32451267
Drug: Sandblasting (surface
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sandblasting (surface treatment)
Study: 32451267
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (surface treatment)
Study: 32451267
Drug: Er:YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Er:YAG laser (surface treatment)
Study: 35178708
Drug: Systemic Family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic Family Therapy added to Treatment As Usual
Study: 34633405
Drug: Aspirin (81
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (81 mg orally once daily; n=164)
Study: 34633405
Drug: Prophylactic-dose apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Prophylactic-dose apixaban (2.5 mg orally twice daily; n=165)
Study: 34633405
Drug: Therapeutic-dose apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Therapeutic-dose apixaban (5 mg orally twice daily; n=164)
Study: 34633405
Drug: Prophylactic-dose apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Prophylactic-dose apixaban
Study: 35241226
Drug: Therapeutic-dose apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Therapeutic-dose apixaban
Study: 32436135
Drug: Mud-bath therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mud-bath therapy with sulfurous-arsenical-ferruginous mineral water
Study: 34726324
Drug: Metformin 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1500 to 2000 mg daily
Study: 32979577
Drug: valaciclovir treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: valaciclovir treatment for 3 months
Study: 32979577
Drug: Development of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Development of IgG anti-N-methyl-D-aspartate receptor (NMDAR) antibodies
Study: 32652616
Drug: Cannabidiol (CBD;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabidiol (CBD; 20 mg/kg/day)
Study: 32652616
Drug: Cannabidiol (CBD;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabidiol (CBD; 20 mg/kg/day) with clobazam (CLB)
Study: 36083324
Drug: High-volume injection
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-volume injection (HVI) - 50 mL
Study: 36083324
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection - 2 mL (saline and lidocaine)
Study: 36083324
Drug: High-volume injection
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-volume injection (HVI)
Study: 37638083
Drug: Methadone (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone (0.2 mg/kg)
Study: 33487095
Drug: Electronic stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic stimulation (ES) administered to bilateral lower legs using tapping mode (3 Hz)
Study: 34051006
Drug: 50 µl
Normalized name: L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 µl Receptal solution
Study: 34051006
Drug: 100 µl
Normalized name: L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 µl Receptal solution
Study: 34051006
Drug: 150 µl
Normalized name: L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 µl Receptal solution
Study: 32601101
Drug: Colon capsule
Normalized name: Sus scrofa colon preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colon capsule endoscopy (CCE) as a filter test prior to faecal immunochemical test (FIT)
Study: 33895547
Drug: internet‐delivered cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: internet‐delivered cognitive behavioral treatment that included exposure (ICBT)
Study: 33895547
Drug: internet‐delivered cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: internet‐delivered cognitive behavioral treatment without exposure (ICBT‐WE)
Study: 35696698
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg capsules
Study: 35696698
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules (Becosules)
Study: 32248747
Drug: JNJ-54175446 (50-450
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-54175446 (50-450 mg)
Study: 32248747
Drug: JNJ-54175446 (≥100
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-54175446 (≥100 mg)
Study: 34627490
Drug: De-escalation (clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: De-escalation (clopidogrel plus aspirin)
Study: 34627490
Drug: Active control
Normalized name: Accu-Chek Active Control Solution
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active control (ticagrelor plus aspirin)
Study: 35296491
Drug: Multinutrient supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multinutrient supplement including vitamin D, tryptophan, long‐chain polyunsaturated fatty acids, and prebiotic dietary fibres (94 kCal per daily dose)
Study: 35296491
Drug: Multinutrient supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multinutrient supplement
Study: 32417629
Drug: Melatonin 10
Normalized name: melatonin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 10 mg (two capsules of 5 mg each) once a day, 1 hour before bedtime for 12 weeks
Study: 35668528
Drug: Ruxolitinib combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib combined with 1 mg/kg methylprednisolone
Study: 35668528
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg methylprednisolone alone
Study: 32543247
Drug: Enoxaparin (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (0.75 mg/kg intra-arterial bolus followed by 0.75 mg/kg/6 hours intravenous infusion)
Study: 32543247
Drug: Standard-of-care (SOC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care (SOC) with unfractionated heparin ± glycoprotein IIb/IIIa antagonist (GPI)
Study: 33258423
Drug: 1×10^5/ml spore
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1×10^5/ml spore suspension
Study: 35873761
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no acupuncture treatment and ASD)
Study: 33827963
Drug: IV infusion
Normalized name: IV INFUSION SET (WINTHROP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion of human adrenomedullin (19.9 pmol/kg/min)
Study: 35493500
Drug: Rituximab (maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (maintenance therapy)
Study: 33568796
Drug: Topiramate (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (200 mg daily for 12 weeks)
Study: 36401384
Drug: Endoscopic variceal
Normalized name: VARICELLA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic variceal obturation (EVO) with tissue glue injection
Study: 35857179
Drug: Tralokinumab 300
Normalized name: TRALOKINUMAB 300 mg in 2 mL SUBCUTANEOUS INJECTION, SOLUTION [Adbry]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tralokinumab 300 mg subcutaneous every 2 weeks (q2w) plus topical corticosteroids (TCS) as needed
Study: 33000503
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus topical corticosteroids (TCS) as needed
Study: 34371870
Drug: 2.6 g
Normalized name: SODIUM BICARBONATE 2.6 g in 2.6 g ORAL POWDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.6 g marine n‐3 PUFA supplement
Study: 35012809
Drug: Colloid group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloid group (6% hydroxyethyl starch 130/0.4 10 mL/kg)
Study: 35012809
Drug: Crystalloid group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crystalloid group (balanced crystalloid solution, Plasma Solution A 10 mL/kg)
Study: 33571166
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no treatment mentioned)
Study: 36387986
Drug: (poly)phenol-rich supplement
Normalized name: Phenol
DrugBank: Phenol (DB03255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: (poly)phenol-rich supplement 1,200 mg/day + hypocaloric diet
Study: 35576997
Drug: Creative Arts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creative Arts Therapy (CAT) program
Study: 33105308
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of TXA bolus/1 g of TXA infusion (bolus maintenance)
Study: 33105308
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of TXA bolus/placebo infusion (bolus only)
Study: 33105308
Drug: Placebo bolus/placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo bolus/placebo infusion (placebo)
Study: 34619312
Drug: Allele 'G'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allele 'G' of rs58379944 and rs11574012; Allele 'A' of rs12581281
Study: 35485346
Drug: Single doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of JNJ-64530440 (up to 4000 mg)
Study: 35485346
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of JNJ-64530440 (750 mg once daily and 2000 mg for 7 days)
Study: 35485346
Drug: Single and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single and multiple doses of JNJ-64530440
Study: 34840276
Drug: Solid Ankle
Normalized name: Bos taurus ankle joint preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solid Ankle Foot Orthosis (AFO) with regular physical therapy for 3 months
Study: 34840276
Drug: Ground Reaction
Normalized name: Turmeric,ground
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ground Reaction Ankle Foot Orthosis (GRAFO) with regular physical therapy for 3 months
Study: 32043473
Drug: Prehospital intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prehospital intravenous antibiotics
Study: 33220122
Drug: CM for
Normalized name: Chondroitin/Dimethyl Sulfone/Glucosamine Sulfate/Inflexil 250 MG-250 MG-500 MG-7.5 MG Oral Tablet [LEGATRIN GCM FORMULA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CM for drugs (n = 27)
Study: 33220122
Drug: CM for
Normalized name: Chondroitin/Dimethyl Sulfone/Glucosamine Sulfate/Inflexil 250 MG-250 MG-500 MG-7.5 MG Oral Tablet [LEGATRIN GCM FORMULA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CM for alcohol and drugs (n = 32)
Study: 36339874
Drug: Humanoid robot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Humanoid robot intervention (Grace humanoid robot, 8-week, twice a week)
Study: 36339874
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (active control)
Study: 33512755
Drug: Omarigliptin 25
Normalized name: Omarigliptin
DrugBank: Omarigliptin (DB11992)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Omarigliptin 25 mg